Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Finafloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 5/20 | 0.43 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Finafloxacin SCHEMBL7610665 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL1002869 | 1.00 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL29378815 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL7664508 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| Finafloxacin SCHEMBL7660879 | 0.99 | ALDH1A1 (0.55) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL9182746 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL8803776 | 0.92 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL15791569 | 0.90 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7610667 | 0.90 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDHSD17B10MEN1 | |
| SCHEMBL7608326 | 0.90 | ALDH1A1 (0.45) | ALDH1A1KDM4EHPGDHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432948-B1 | ANTIULCER AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-13 | — | — | US | disclosed |
| EP-0946176-B1 | THE USE OF 7-(2-OXA-5,8-DIAZABICYCLO 4.3.0]NON-8-YL)-QUINOLONE CARBOXYLIC ACID AND NAPHTHYRIDON CARBOXYLIC ACID DERIVATIVES FOR MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HELICOBACTER PYLORI INFECTIONS AND ASSOCIATED GASTRODUODENAL DISEASES | BAYER AG (DE) | 2002-03-27 | — | — | EP | disclosed |
| US-6133260-A | Use of 7-(2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-quinolone carboxylic acid and naphthyridon carboxylic acid derivatives for the treatment of Helicobacter pylori infections and associated gastroduodenal diseases | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-17 | — | — | US | disclosed |